Filing Details

Accession Number:
0001638599-16-001487
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-03 18:11:50
Reporting Period:
2016-11-01
Filing Date:
2016-11-03
Accepted Time:
2016-11-03 18:11:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1060736 Seattle Genetics Inc SGEN Biological Products, (No Disgnostic Substances) (2836) 911874389
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1087939 Julian Baker 667 Madison Avenue, 21St Floor
New York NY 10065
Yes No Yes No
1087940 Felix Baker 667 Madison Avenue, 21St Floor
New York NY 10065
Yes No Yes No
1263508 Baker Bros. Advisors Lp 667 Madison Avenue, 21St Floor
New York NY 10065
Yes No Yes No
1363364 Baker Brothers Life Sciences Lp 667 Madision Avenue, 21St Floor
New York NY 10065
Yes No Yes No
1551139 667, L.p. 667 Madision Avenue, 21St Floor
New York NY 10065
Yes No Yes No
1580575 Baker Bros. Advisors (Gp) Llc 667 Madision Avenue, 21St Floor
New York NY New York
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-11-01 9,347 $54.93 4,725,245 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-11-01 85,353 $54.93 39,517,849 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-11-01 197 $54.61 4,725,442 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-11-01 1,803 $54.61 39,519,652 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-11-01 101 $54.51 4,725,543 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-11-01 924 $54.51 39,520,576 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 4,417 $54.37 4,729,960 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 40,332 $54.37 39,560,908 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 3,583 $53.66 4,733,543 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 32,717 $53.66 39,593,625 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 266 $53.33 4,733,809 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 2,434 $53.33 39,596,059 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 316 $51.83 4,734,125 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-01 2,884 $51.83 39,598,943 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 31,679 $56.26 4,765,804 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 289,278 $56.26 39,888,221 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 2,889 $56.13 4,768,693 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 26,381 $56.13 39,914,602 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 689 $56.12 4,769,382 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 6,289 $56.12 39,920,891 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 365 $55.87 4,769,747 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 3,335 $55.87 39,924,226 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 10,434 $55.84 4,780,181 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-02 95,280 $55.84 40,019,506 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-03 37,392 $56.91 4,817,573 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-03 341,438 $56.91 40,360,944 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-03 50 $56.55 4,817,623 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-11-03 456 $56.55 40,361,400 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 107,511 Direct
Common Stock 107,504 Direct
Footnotes
  1. Reflects shares of common stock of Seattle Genetics, Inc. (the "Issuer") held directly by Felix J. Baker.
  2. Reflects shares of common stock of the Issuer held directly by Julian C. Baker.
  3. The price reported in Column 4 is a weighted average price. These shares were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences") in multiple transactions at prices ranging from $54.35 to $54.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  4. After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  5. After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences
  6. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $54.60 to $54.62, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $54.39 to $54.63, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $54.32 to $54.72, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  9. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $53.62 to $53.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  10. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $53.19 to $53.59, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  11. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $51.78 to $51.94, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  12. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $55.78 to $56.37, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  13. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $55.50 to $56.35, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  14. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $55.96 to $56.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  15. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $55.74 to $55.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  16. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $55.45 to $56.20, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  17. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $56.50 to $57.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  18. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $56.51 to $56.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  19. Includes beneficial ownership of 14,400 previously issued restricted stock units payable solely in common shares issued to Felix Baker in his capacity as a director of the Issuer pursuant to the Amended and Restated 2007 Equity Incentive Plan of which the fund may be deemed to own a portion and 30,000 shares received previously from exercise of 30,000 stock options of the Issuer that were issued to Felix J. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.
  20. Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to Life Sciences and 667 (collectively the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.
  21. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.